Showing results (71-80 of 374) with videos related to
Sort By:
Pageof 38
Clinical Psychology Review|June 10, 2008
The conceptualization and measurement of therapeutic alliance: an empirical reviewRachel Elvins, Jonathan GreenProgress in Brain Research|November 19, 2018
Studying child development in genetic models of ASDShruti Garg, Jonathan GreenOncology (Williston Park, N.Y.)|February 3, 2005
Gemcitabine/Irinotecan/celecoxib in pancreatic cancerAllan Lipton, Harold Harvey, Lois Witters, et al.American Journal of Clinical Oncology|February 11, 2003
Decreased response to paclitaxel versus docetaxel in HER-2/neu transfected human breast cancer cellsLois M Witters, Samuel M Santala, Linda Engle, et al.International Journal of Oncology|January 16, 2003
Epidermal growth factor receptor mRNA in peripheral blood of patients with pancreatic, lung, and colon carcinomas detected by RT-PCRLoren E Clarke, Kim Leitzel, Jill Smith, et al.The Oncologist|October 5, 2007
Zoledronic acid and survival in breast cancer patients with bone metastases and elevated markers of osteoclast activityAllan Lipton, Richard J Cook, Pierre Major, et al.Current Medical Research and Opinion|November 19, 2010
Zoledronic acid therapy impacts risk and frequency of skeletal complications and follow-up duration in prostate cancer patients with bone metastasisHind T Hatoum, Swu-Jane Lin, Amy Guo, et al.Breast Cancer Research and Treatment|June 25, 2010
Prognostic factors for skeletal complications from metastatic bone disease in breast cancerJanet E Brown, Richard J Cook, Allan Lipton, et al.Clinical Breast Cancer|June 14, 2011
Treatment persistence with monthly zoledronic acid is associated with lower risk and frequency of skeletal complications in patients with breast cancer and bone metastasisHind T Hatoum, Swu-Jane Lin, Matthew R Smith, et al.American Journal of Clinical Oncology|August 5, 2009
Phase I trial of zoledronic acid + imatinib mesylate (Gleevec) in patients with bone metastasesAllan Lipton, Cynthia Campbell-Baird, Harold Harvey, et al.Pageof 38